Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
In liver disease, extent of tissue damage depends on the balance between the generation of scar tissue and the regeneration of new liver cells. In a significant minority of people who get injury to their organs instead of repairing them, they form scars.
"The idea is that we're using the most appropriate technology to address individual clinical questions rather than just focusing on one technique," explains EAE President Dr Luigi Badano, from the University of Padua, Italy.
Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).
Heart rate recovery at one minute after a six-minute walking distance (6MWD) test is highly predictive of clinical worsening and time to clinical worsening in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a new study.
NewYork-Presbyterian Hospital/Columbia University Medical Center has officially opened the Center for Acute Respiratory Failure, which offers, among other services, expertise in using lung bypass technology to help adult patients whose lungs are rapidly shutting down.
The Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford today announced that it will host the 11th Annual Race Against PH in conjunction with the Pulmonary Hypertension Association's 6-Minute Marathon. These events provide patients with an opportunity to walk or jog alongside their families and friends, to help increase awareness of the disease, and to help raise money to find a cure.
Surgeons at UK HealthCare recently became the first ever to perform two specific procedures together as a bridge to lung transplantation. Wanda Craig, of Lexington, Ky., is the first patient in history to receive these procedures, and at the age of 68, she is also the oldest living human to be bridged to transplant using an artificial lung device, also known as an extracorporeal membrane oxygenation (ECMO).
As the month of November kicks off PH Awareness Month, Dr. Ronald Oudiz - lead investigator at the Los Angeles Biomedical Research Institute (LA BioMed) - hopes to bring greater awareness to this disorder that has affected the lives of so many. Dr. Oudiz is a pioneer in this field, having received the 2011 Award for Excellence earlier this year from the Pulmonary Hypertension Association for his dedication to find new ways to treat this often fatal disease.
A drug treatment has been proven to prevent lesions from cerebral cavernous malformation — a brain blood vessel abnormality that can cause bleeding, epilepsy and stroke — for the first time in a new study.
A protein critical to development appears to have a grave impact on lungs exposed to smoking and air pollution, researchers report.
By studying mice exposed to tobacco smoke for a period of months, researchers have new insight into how emphysema and chronic obstructive pulmonary disease (COPD) develop.
The Pulmonary Hypertension Association Europe (PHA EU) has launched ‘Time Matters’ a new campaign which encourages people with Pulmonary Hypertension (PH) and their friends and family to share hopes and dreams for the future in order to raise awareness of this deadly and rapidly progressive condition. By logging on to the website http://phtimematters.org and posting an entry, everybody can help the patient association take a step towards increased awareness and understanding of this devastating condition.
UCLA researchers have found that the hormone estrogen may help reverse advanced pulmonary hypertension, a rare and serious condition that affects 2 to 3 million individuals in the U.S., mostly women, and can lead to heart failure.
A new report from scientists at Massachusetts General Hospital (MGH) and their colleagues in centers around the world finds that common variants in 28 regions of DNA are associated with blood pressure in human patients.
A new blood test is being developed by researchers in Cambridge and Oxford, which, for the first time, could help identify babies at risk of a severe form of sickle cell disease, allowing immediate and more intensive treatment to be given, thanks to a grant from children's charity Action Medical Research.
New ESC guidelines emphasise the importance of screening and risk assessment. Pre-existing heart disease is rarely a contraindication to pregnancy - indeed, many women with heart disorders tolerate pregnancy well - but it remains a "major concern" that complications are frequent and in some cases may be life-threatening for both the mother and her child. In Europe maternal heart disease has now become the major cause of maternal death during pregnancy.
L'Association Québécoise de l'HPN regrets that Quebec remains one of the only jurisdictions in the developed world to decline including the only effective life-saving treatment against an ultra-rare blood disease - paroxysmal nocturnal hemoglobinuria (PNH) - on its public drug insurance plan drugs list.
Children born with heart defects that pummel their lungs with up to three times the normal blood volume quickly find their lungs in jeopardy as well.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
A new study by researchers at Hospital for Special Surgery has identified patients who are at a higher risk of morbidity and mortality when undergoing knee replacement surgery in both legs at the same time.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.